Manufacturers, Compounders Clash As FDA Prepares Final Offer On Office Compounding
Executive Summary
Pharmaceutical manufacturers and compounders are in opposition over the US FDA’s plans to carve out a place for pharmacies that want to keep physicians’ offices stocked with small amounts of product. Who will the agency disappoint this time?
You may also be interested in...
FDA Ups Pressure On Stem Cell Therapy Makers To Follow Product Approval Rules
US FDA is frustrated that few stem cell therapy makers are seeking regulatory approval of their products during the current enforcement grace period.
FDA’s Revised Draft For Compounding Pharmacies Opens Door To Compounding For Office Use
FDA’s revised draft guidance on GMPs for outsourcing pharmacy compounding operations responds to calls to allow the compounding of small quantities of drugs presumably for office use. The IACP applauds the move.
Survey Shows Drug Makers Don't Expect To Begin Serializing All Packages By November Deadline
Concerns that the US pharmaceutical industry will not have the necessary serialization systems in place to fully comply with DSCSA product package serialization requirement appear to be bearing fruit, according to a recent survey.